Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression

Neoplasma

Volumn 56, Issue 4, 2009, Pages 284-290

  Hlobilkova, A ^a   Ehrmann, J ^a   Knizetova, P ^a   Krejci, V ^a   Kalita, O ^a   Kolar, Z ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Angiogenesis; Astrocytoma; MMP 9 and immunohiostochemistry; Nestin; VEGF

Indexed keywords

GELATINASE B; NESTIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; INTERMEDIATE FILAMENT PROTEIN; NERVE PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ASTROCYTOMA; CANCER GROWTH; CANCER STAGING; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROTEIN EXPRESSION; ADOLESCENT; BRAIN TUMOR; CHILD; DISEASE COURSE; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERMEDIATE FILAMENT PROTEINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NERVE TISSUE PROTEINS; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOUNG ADULT;

EID: 68149117525     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2009_04_284     Document Type: Article

References (42)

1. Von Deimling A, LOUIS DN, Von AMMON K et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992; 77: 295-301. doi:10.3171/jns.1992.77. 2.0295
2. JAMES CD, CARLBOM E, DUMANSKI JP et al. Clonal genomic alterations in glioma malignancy stages. Cancer Res 1988; 48: 5546-5551.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31. doi:10.1038/nm0195-27
4. Weidner N. Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow. J Pathol 1998 (184: 130-135.
5. Maeda K, CHUNG YS, TAKATSUKA S et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer 1995; 72: 319-323.
6. FALLOWFIELD ME, COOK MG. The vascularity of primary cutaneous melanoma. J Pathol 1991; 164: 241-244. doi:10.1002/path.1711640309
7. LEON SP, FOLKERTH RD, BLACK PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77: 362-372. doi:10.1002/(SICI)1097- 0142(19960115)77:2<362::AID-CNCR20>3.0.CO;2-Z
8. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000; 55:15-35 discussion 35-36.
9. KIM KJ, LI B, WINER J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 6423: 841-844.
10. OEHRING RD, MILETIC M, VALTER MM et al. Vascular endothelial growth factor (VEGF) in astrocytic gliomas-a prognostic factor? J Neurooncol 1999; 45: 117-125. doi:10.1023/A:1006333005563
11. Plate Kh, Breier G, WEICH HA et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 6398: 845-848. doi: 10.1038/359845a0
12. Fischer I, GANGER JP, LAW M et al. Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol. 2005; 4: 297-310.
13. Jain K, Tomaso E, DUDA DG et al. Angiogenesis in brain tumours. Nature Rev Neurosci 2007; 8: 610-622. doi:10.1038/ nrn2175
14. Klagsbrun M, D'AMORE PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996; 7: 259-270. doi:10.1016/S1359- 6101(96)00027-5
15. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22.
16. Soker S, Takashima S, MIAO HQ et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745. doi:10.1016/S0092-8674(00) 81402-6
17. Dahlstrand J, COLLINS VP, LENDAHL U et al. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992; 52: 5334-5341.
18. Sugawara K, Kurihara H, Negishi M et al. Nestin as a marker for proliferative endothelium in gliomas. Lab Invest 2002; 82: 345-351.
19. Westermarck J, KÄHÄRI VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-792.
20. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-21494. doi:10.1074/jbc.274.31.21491
21. Pagenstecher A, WUSSLER EM, OPDENAKER G et al. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol 2001; 60: 598-612.
22. FORSYTH PA, WONG H, LAING TD et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999; 79:1828-1835. doi:10.1038/sj.bjc.6690291
23. Bergers G, Brekken R, McMahon G et al. Matrix metalloproteinase- 9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2:737-744. doi:10.1038/35036374
24. Fina L, MOLGAARD HV, ROBERTSON D et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990; 75: 2417-2426.
25. Loggini B, Boldrini L, Gisfredi S et al. CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma. Pathol Res Pract 2003; 199: 705-712. doi:10.1078/0344-0338- 00486
26. Karavasilis V, Malamou-Mitsi V, Briasoulis E et al. Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer 2006; 16 Suppl 1: 241-246. doi:10.1111/ j.1525-1438.2006.00316.x
27. Karavasilis V, Malamou-Mitsi V, Briasoulis E et al. Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer 2005; 5: 25. doi:10.1186/1471-2407-5-25
28. CAVENNE WK, BIGNER DD, NEWCOMB EW et al. Astrocytic tumours. In: Kleihues P, Cavenee WK, editors. Pathology and genetics of tumour of the nervous system. Lyon: IARC, 1997: 1-36.
29. Hlobilkova A, Ehrmann J, Sedlakova E et al. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression? Neoplasma 2007; 54(4): 334-341.
30. Berse B, Brown LF, Van de WATER Let al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-220.
31. Knizetova P, Ehrmann J, Hlobilkova A et al. Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell cycle 2008 7(16): 2553-2561.
32. Han H, SILVERMAN JF, SANTUCCI TS et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001; 8: 72-79. doi:10.1007/s10434-001- 0072-y
33. Bando H, WEICH HA, BROKELMANN M et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 2005; 92: 553-561.
34. Ichikura T, Tomimatsu S, Ohkura E et al. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol 2001; 78: 132-137. doi:10.1002/jso.1133
35. Huang H, Held-Feindt J, Buhl R et al. Expression of VEGF and its receptors in different brain tumors. Neurol Res 2005; 27: 371-377. doi:10.1179/016164105X39833
36. Decaussin M, Sartelet H, Robert C et al. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 1999; 188: 369-377. doi:10.1002/(SICI)1096- 9896(199908)188:4<369::AID-PATH381>3.0.CO;2-X
37. WEINER LM. Building better magic bullets-improving unconjugated monoclonal antibody therapy for cancer. Nat Rev Cancer 2007; 7: 701-706. doi:10.1038/nrc2209
38. Brandsma D, Van den BENT MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol 2007; 19: 598-605. doi:10.1097/CCO.0b013e3282f0313b
39. REARDON DA, WEN PY, DESJARDINS A et al. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opin Biol Ther 2008; 8(4): 541-553. doi:10.1517/ 14712598.8.4.541
40. Schiffer D, Manazza A, Tamango I. Nestin expression in neuroepithelial tumors. Neurosci Lett 2006; 400: 80-85. doi:10.1016/j.neulet.2006.02.034
41. Mokry J, Cizkova D, Filip S et al. Nestin expression by newly formed human blood vessels. Stem Cells Dev 2004; 13: 658-664. doi:10.1089/scd.2004.13. 658
42. STEINDLER DA, LAYWELL ED. Astrocytes as stem cells: nomenclature, phenotype, and translation. Glia 2003; 43: 62-69. doi:10.1002/glia.10242